secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023481
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance
--------------------------------------------------------------------------------

- Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.
- Net loss $11.2M ($0.23/diluted) vs $3.9M loss ($0.08) YoY; adjusted EBITDA $3.2M vs $7.2M.
- Full-year revenue growth reaffirmed 20-23%; raised gross margin guidance to 74% and adjusted EBITDA margin to 26%.
- ~400 MACI Arthro surgeons trained; YTD biopsy growth >30% for trained surgeons; NexoBrid +207% YoY.
- Cash $162M, no debt; tariffs expected negligible impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/0001628280-25-023481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/vcel-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer